D.A. Davidson & Co’s Myriad Genetics MYGN Stock Holding History

D.A. Davidson & Co’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,699	Closed	-$95K	–	1661
2017 Q2	$95K	Buy	3,699 +210	+6%	+$4.46K	﹤0.01%	1287
2017 Q1	$66K	Buy	3,489 +2,889	+482%	+$51.2K	﹤0.01%	1408
2016 Q4	$10K	Buy	600 +200	+50%	+$3.62K	﹤0.01%	2118
2016 Q3	$8K	Hold	400	–	–	﹤0.01%	2101
2016 Q2	$12K	Hold	400	–	–	﹤0.01%	1916
2016 Q1	$14K	Sell	400 -150	-27%	-$5.65K	﹤0.01%	1823
2015 Q4	$23K	Sell	550 -10,426	-95%	-$440K	﹤0.01%	1667
2015 Q3	$410K	Sell	10,976 -198	-2%	-$7.03K	0.01%	594
2015 Q2	$379K	Sell	11,174 -203	-2%	-$6.9K	0.01%	651
2015 Q1	$402K	Sell	11,377 -572	-5%	-$20.5K	0.01%	634
2014 Q4	$406K	Buy	11,949 +11,849	+11,849%	+$420K	0.01%	642
2014 Q3	$3K	Buy	+100	New	+$3.73K	﹤0.01%	2000
2014 Q1	–	Sell	-294	Closed	-$6K	–	2160
2013 Q4	$6K	Buy	+294	New	+$7.44K	﹤0.01%	1821

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

D.A. Davidson & Co's MYGN Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Myriad Genetics (MYGN) in Q3 2017, closing a stake of 3,699 shares — an estimated $95K sold.

D.A. Davidson & Co first reported a position in MYGN in Q4 2013 and held it in 13 quarters. The position peaked at $410K in Q3 2015. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

D.A. Davidson & Co reported no remaining Myriad Genetics position as of Q3 2017 after selling out during the quarter.
D.A. Davidson & Co sold 3,699 Myriad Genetics shares in Q3 2017, an estimated $95K.
D.A. Davidson & Co first reported a position in Myriad Genetics in Q4 2013 and held it in 13 quarters.
D.A. Davidson & Co's Myriad Genetics position peaked at $410K in Q3 2015.
220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.